Roivant Sciences Ltd. ROIV

Revenue Intelligence Report • 15 quarters of SEC filing data • Updated 2026-03-15

Roivant Sciences Ltd. has a forecasted full-year revenue of $5.1M, a -65.2% year-over-year change, based on 15 quarters of SEC filing data. Key revenue drivers include SG&A (elasticity 0.18x). The ARDL model has 14.4% MAPE.

Investment Thesis

At 14.4% MAPE, the model captures Roivant Sciences Ltd.'s broad revenue trajectory, though quarterly variability suggests sensitivity to external factors. R&D spending currently shows a negative elasticity (-5.82x), which can indicate heavy investment in long-cycle initiatives not yet reflected in revenue. Sales & marketing spend shows a 0.18x elasticity, suggesting effective go-to-market execution.

Next FY Revenue
$5.13M
-65.2% YoY
R&D Elasticity
-5.82x
SG&A Elasticity
0.18x
Model Accuracy
14.4% MAPE
Holdout validation: The model predicted $2.2M vs the actual $2.0M — an error of 7.8%.
⚠ Model limitation: This company shows negative spending multipliers, meaning increases in spending have not directly translated into revenue growth. This typically occurs with commodity-driven companies or hypergrowth companies.

Revenue Forecast

ROIV Revenue Forecast

Quarterly Detail

QuarterModel ForecastActual95% RangeYoY GrowthStatus
Q4 2025 $2.2M $2.0M $1.5M – $3.1M -51.8% ✓ In range
Q2 2026 $1.7M $1.0M – $2.9M -81.0%
Q3 2026 $1.4M $0.7M – $2.6M -36.9%
Q4 2026 $1.1M $0.5M – $2.4M -28.1%
Q1 2027 $0.9M $0.4M – $2.1M -54.1%

How Spending Drives Revenue

ROIV Spending Timing
Reading this chart: Each line shows the cumulative elasticity — how a 1% increase in spending translates to revenue growth over subsequent quarters. The effect builds over 4-5 quarters as investments compound.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch

Data sourced from SEC EDGAR XBRL filings. Model: ARDL (log-log) with 15 quarters. This analysis is for informational purposes only and does not constitute investment advice.